Targeting hyperglucagonemia as a complementary therapeutic tactic for insulin treatment in T1D has resulted in several strategies, including brown adipose tissue transplantation (by an unknown mechanism, potentially through secreted factors’ effects on insulin receptor) (8–13) and use of glucagon receptor antagonists (14–17), antibodies (18), or chemical compounds (19). Here, INS is linked to type 1 diabetes mellitus.